The city of Birmingham, Alabama, currently has 2 active clinical trials seeking participants for Hepatitis B research studies.
Study of Oral TLR8 Agonist Selgantolimod on HBsAg in Participants With Both Chronic Hepatitis B and HIV
Recruiting
The study aims to assess safety and tolerability of oral toll-like receptor (TLR) 8 agonist Selgantolimod (SLGN) administered for 24 weeks in participants with both CHB and HIV who have been receiving suppressive antiviral therapy for both viruses for ≥5 years and have qHBsAg level >1000 (3 log10) IU/mL at screening. The study will also evaluate if TLR8 stimulation with SLGN will reduce hepatitis B surface antigen (HBsAg) titers in the blood.
Gender:
All
Ages:
Between 18 years and 70 years
Trial Updated:
04/16/2024
Locations: Alabama CRS, Birmingham, Alabama
Conditions: Hepatitis B, HIV Infections
Reducing Vertical Transmission of Hepatitis B in Africa
Recruiting
Hepatitis B virus is an infection that can be easily transmitted from women to newborns at the time of delivery. Our objective is to identify novel options that are effective and safe in preventing perinatal transmission of hepatitis B in Africa. The REVERT-B study (Reducing Vertical Transmission of Hepatitis B in Africa) is a clinical trial designed to test a new strategy of using antiviral medication in high-risk pregnant women and newborns to reduce the risk of hepatitis B transmission. The s... Read More
Gender:
Female
Ages:
Between 16 years and 50 years
Trial Updated:
10/19/2023
Locations: University of Alabama at Birmingham, Birmingham, Alabama
Conditions: Hepatitis B Infection